InvestorsHub Logo
Followers 15
Posts 240
Boards Moderated 0
Alias Born 01/31/2018

Re: oregonpdx post# 75526

Wednesday, 05/06/2020 7:03:26 PM

Wednesday, May 06, 2020 7:03:26 PM

Post# of 233483
Yang's brief talk:

3 of 7 slides totally about leronlimab: a) ucla blood work justifying studies (suggestive only), b) MOA - RANTES is a "beacon protein" trafficking too many immune cells into damaged areas; c) summary and positive comments on Patterson paper. No outcome mentions.

On early slide, listed with "IL-6r blockers" as candidate for damage limitation phase. Slide showing list of all UCLA studies showed all three leronlimab open, w/ 25 compassionate use. Only 2 in RCTs but they have only been open 5 days.

Slide on Remdesivir balanced - only relevant in early virus replication phase.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News